Ataraxis launches AI model to improve breast cancer risk assessment and reduce unnecessary treatments

Ataraxis, a startup that launched recently, has created an AI model called Ataraxis Breast. This model predicts breast cancer risk with up to 30% more accuracy than current tests, helping doctors determine if aggressive treatment is necessary. The company raised $4 million in seed funding and aims to reduce unnecessary chemotherapy for thousands of patients. Ataraxis Breast was developed using data from over 4,500 breast cancer patients and combines multiple prediction models for improved accuracy. Ataraxis plans to conduct further studies and expand its technology to other cancers. The software is expected to be available for doctors by early 2025.